HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AM Cosmetics' CEO Zimmerman Outlines Plan To Double Brand Sales

This article was originally published in The Rose Sheet

Executive Summary

AM Cosmetics' newly appointed President and CEO Arnie Zimmerman is looking to double sales of each of the company's 10 value-priced brands within three years through expanded distribution and new introductions. Zimmerman recently succeeded Vince Wasik as the head of the firm.

You may also be interested in...



AM Cosmetics

Value-branded cosmetics firm seeking president and CEO after Arne Zimmerman announced intentions to step down at the end of the year. CFO Stephen Heit has been named acting president until the board finds permanent replacement. Both internal and external candidates will be considered for the position, which Zimmerman has held since joining AM Cosmetics in 1999 (1"The Rose Sheet" Feb. 15, 1999, p. 9). Zimmerman is credited with triggering a turnaround at AM Cosmetics. The company, which counts Wet n' Wild and Jonel among its brands, expects 2001 to be its most profitable year ever, Heit says. Zimmerman, also a CTFA board member, has left to pursue "new challenges"...

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Latest Headlines
See All
UsernamePublicRestriction

Register

RS006293

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel